{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T16:10:06Z","timestamp":1756397406622,"version":"3.44.0"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>In opioid treatment programs (OTPs), restarting methadone after missed doses is common. Current guidelines recommend significant dose decreases but do not account for maintained tolerance.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate the safety and treatment retention associated with a novel methadone restart protocol.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cohort study included participants in a public, safety-net OTP in Colorado, comparing cohorts before (2021) and after (2023) a 2022 protocol change. Eligible participants were patients who restarted methadone after 4 or more missed dosing days. Data were analyzed August 2024 through June 2025.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Restart protocol incorporating patient-reported nonprescribed opioid use and individualized assessments to determine restart doses.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Protocol implementation was measured by change in dose before vs after restart, comparing preimplementation and postimplementation periods. Primary outcome was patient safety, measured by emergency department (ED) visits within 7 days of restart (all-cause, opioid withdrawal, and overdose-related) and 7-day and 90-day all-cause mortality. The secondary outcome was 90-day treatment retention. Generalized estimating equations were used to calculate adjusted risk ratios (aRRs) comparing preimplementation and postimplementation periods, controlling for demographics and comorbid substance use. Patient and clinician satisfaction and perceived safety were surveyed.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 786 patients were included in the preimplementation cohort and 780 in the postimplementation cohort; 202 patients had methadone restarts before implementation (464 restart episodes; 124 male [61.4%]; 148 ages 25 to 44 years [73.3%]; 10 Black [5.0%], 72 Hispanic [35.6%], 112 White [55.4%]) and 195 patients after implementation (489 restart episodes; 116 male [59.5%]; 123 ages 25 to 44 years [63.1%]; 12 Black [6.2%], 60 Hispanic [30.8%], 114 White [58.5%]). Most patients were insured by Medicaid (preimplementation, 164 of 202 patients [81.2%]; postimplementation, 154 of 195 patients [79.0%]). In the preimplementation period, restart doses were 32.8% lower (95% CI, 30.8%-34.7%) than the last dose prior to restart. After protocol implementation, restart doses were 3.4% lower (95% CI, 1.5%-5.3%) than the last received dose. In the preimplementation period, 44 of 464 restarts (9.5%) were followed by ED visits within 7 days, compared with 30 of 489 restarts (6.1%) in the postimplementation period (aRR, 0.61; 95% CI, 0.37-0.98). There were 4 restarts followed by death within 90 days in both the preimplementation and postimplementation periods. Treatment retention was similar in preimplementation and postimplementation periods (aRR, 0.88; 95% CI, 0.73-1.05). Survey responses indicated high acceptance and satisfaction with the protocol.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study of individuals with opioid use disorder restarting methadone after a gap in treatment, an individualized methadone restart protocol that considered interim opioid tolerance was associated with higher restart doses without compromising safety or treatment retention. Further research is needed to evaluate if this approach improves treatment outcomes.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.29393","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T15:31:14Z","timestamp":1756395074000},"page":"e2529393","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of a Novel Patient-Centered Methadone Restart Protocol"],"prefix":"10.1001","volume":"8","author":[{"given":"Paul J.","family":"Christine","sequence":"first","affiliation":[{"name":"Department of General Internal Medicine, Denver Health and Hospital Authority, Denver, Colorado"},{"name":"Division of General Internal Medicine, Department of Medicine, University of Colorado School of Medicine, Aurora"},{"name":"Center for Addiction Medicine, Denver Health and Hospital Authority, Denver, Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Blum","sequence":"additional","affiliation":[{"name":"Center for Addiction Medicine, Denver Health and Hospital Authority, Denver, Colorado"},{"name":"Outpatient Behavioral Health Services, Denver Health and Hospital Authority, Denver, Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra R.","family":"Tillman","sequence":"additional","affiliation":[{"name":"Center for Addiction Medicine, Denver Health and Hospital Authority, Denver, Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannan M.","family":"Braun","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Denver Health and Hospital Authority, Denver, Colorado"},{"name":"Division of General Internal Medicine, Department of Medicine, University of Colorado School of Medicine, Aurora"},{"name":"Center for Addiction Medicine, Denver Health and Hospital Authority, Denver, Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Hinrichs","sequence":"additional","affiliation":[{"name":"Center for Addiction Medicine, Denver Health and Hospital Authority, Denver, Colorado"},{"name":"Outpatient Behavioral Health Services, Denver Health and Hospital Authority, Denver, Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermione","family":"Hurley","sequence":"additional","affiliation":[{"name":"Center for Addiction Medicine, Denver Health and Hospital Authority, Denver, Colorado"},{"name":"Division of Infectious Diseases, Department of Medicine, Denver Health and Hospital Authority, Denver, Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alia","family":"Al-Tayyib","sequence":"additional","affiliation":[{"name":"Center for Addiction Medicine, Denver Health and Hospital Authority, Denver, Colorado"},{"name":"Public Health Institute at Denver Health, Denver Health and Hospital Authority, Denver, Colorado"},{"name":"Center for Health Systems Research, Office of Research, Denver Health and Hospital Authority, Denver, Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"zoi250826r1","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"issue":"3","key":"zoi250826r2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study.","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"issue":"1","key":"zoi250826r4","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1097\/ADM.0000000000001032","article-title":"Methadone dose, cannabis use, and treatment retention: findings from a community-based sample of people who use unregulated drugs.","volume":"17","author":"Lake","year":"2023","journal-title":"J Addict Med"},{"key":"zoi250826r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108832","article-title":"Adapting methadone inductions to the fentanyl era.","volume":"141","author":"Buresh","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"zoi250826r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2023.209004","article-title":"Safety of rapid inpatient methadone initiation protocol: a retrospective cohort study.","volume":"148","author":"Racha","year":"2023","journal-title":"J Subst Use Addict Treat"},{"key":"zoi250826r12","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-024-09341-1","article-title":"Early results of implementing rapid methadone titration for hospitalized patients: a case series.","author":"Martin","year":"2025","journal-title":"J Gen Intern Med"},{"issue":"5","key":"zoi250826r13","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/ADM.0000000000001362","article-title":"Induction to methadone 80 mg in the first week of treatment of patients who use fentanyl: a case series from an outpatient opioid treatment program.","volume":"18","author":"Steiger","year":"2024","journal-title":"J Addict Med"},{"issue":"7577","key":"zoi250826r14","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1136\/bmj.39016.471840.68","article-title":"Methadone tolerance testing in drug misusers.","volume":"333","author":"Bakker","year":"2006","journal-title":"BMJ"},{"issue":"7","key":"zoi250826r15","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.ejpain.2007.12.012","article-title":"Antinociceptive effects of high-dose remifentanil in male methadone-maintained patients.","volume":"12","author":"Hay","year":"2008","journal-title":"Eur J Pain"},{"issue":"3","key":"zoi250826r16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.pain.2005.11.005","article-title":"Methadone maintenance patients are cross-tolerant to the antinociceptive effects of very high plasma morphine concentrations.","volume":"120","author":"Athanasos","year":"2006","journal-title":"Pain"},{"issue":"10","key":"zoi250826r17","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1080\/10826084.2018.1432646","article-title":"Comparing the validity of self-report and urinalysis for substance use among former inmates in the Northeastern United States.","volume":"53","author":"van den Berg","year":"2018","journal-title":"Subst Use Misuse"},{"key":"zoi250826r18","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.109769","article-title":"Self-report and urine drug screen concordance among women with co-occurring PTSD and substance use disorders participating in a clinical trial: impact of drug type and participant characteristics.","volume":"244","author":"Ruglass","year":"2023","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"zoi250826r19","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.jaac.2023.04.007","article-title":"Editorial: inconclusive (or \u201celusive\u201d): concordance between substance use self-report and toxicology for diverse youth populations.","volume":"62","author":"Fortuna","year":"2023","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"zoi250826r20","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/10826084.2021.2019783","article-title":"Agreement between youth self-report and biospecimen-confirmed substance use: a systematic review.","volume":"57","author":"Folk","year":"2022","journal-title":"Subst Use Misuse"},{"issue":"10","key":"zoi250826r21","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1111\/add.15004","article-title":"Do interruptions to the continuity of methadone maintenance treatment in specialist addiction settings increase the risk of drug-related poisoning deaths? A retrospective cohort study.","volume":"115","author":"Durand","year":"2020","journal-title":"Addiction"},{"issue":"8","key":"zoi250826r22","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1111\/add.14188","article-title":"The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom.","volume":"113","author":"Hickman","year":"2018","journal-title":"Addiction"},{"issue":"9","key":"zoi250826r23","doi-asserted-by":"publisher","first-page":"943","DOI":"10.2105\/AJPH.2023.307335","article-title":"A mortality surveillance collaboration between a health system and public health department.","volume":"113","author":"Simpson","year":"2023","journal-title":"Am J Public Health"},{"issue":"16","key":"zoi250826r24","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1007\/s11606-024-08909-1","article-title":"Improving identification of patients experiencing homelessness in the electronic health record: a curated registry approach.","volume":"39","author":"Stella","year":"2024","journal-title":"J Gen Intern Med"},{"issue":"2","key":"zoi250826r25","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support.","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"issue":"9","key":"zoi250826r28","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","article-title":"Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis.","volume":"78","author":"Santo","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"zoi250826r29","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1111\/add.16473","article-title":"Target trial emulation for comparative effectiveness research with observational data: promise and challenges for studying medications for opioid use disorder.","volume":"119","author":"Christine","year":"2024","journal-title":"Addiction"},{"issue":"5","key":"zoi250826r30","doi-asserted-by":"publisher","DOI":"10.1093\/haschl\/qxaf101","article-title":"Predictors of non-transport by emergency medical services after a nonfatal opioid overdose: a national analysis.","volume":"3","author":"Taylor","year":"2025","journal-title":"Health Aff Sch"},{"key":"zoi250826r31","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103296","article-title":"Refusal to accept emergency medical transport following opioid overdose, and conditions that may promote connections to care.","volume":"97","author":"Bergstein","year":"2021","journal-title":"Int J Drug Policy"},{"key":"zoi250826r7","volume-title":"Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. Vol DHHS Publication No. (SMA) 06-4214","author":"Substance Abuse and Mental Health Services Administration","year":"2005"},{"key":"zoi250826r3","unstructured":"Substance Abuse and Mental Health Services Administration. Federal guidelines for opioid treatment programs. Fall 2024. Accessed December 10, 2024. https:\/\/library.samhsa.gov\/sites\/default\/files\/federal-guidelines-opioid-treatment-pep24-02-011.pdf"},{"key":"zoi250826r5","unstructured":"Substance Abuse and Mental Health Services Administration. Medications for opioid use disorder. Publication No. PEP21-02-01-002. July 2021. Accessed March 31, 2025. https:\/\/library.samhsa.gov\/product\/tip-63-medications-opioid-use-disorder\/pep21-02-01-002"},{"key":"zoi250826r6","unstructured":"Leavitt? SB. Methadone dosing and safety in the treatment of opioid addiction. Addiction Treatment Forum. Published online September 2003. Accessed June 15, 2024. https:\/\/atforum.com\/documents\/DosingandSafetyWP.pdf"},{"key":"zoi250826r8","unstructured":"World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Published online January 1, 2009. Accessed March 31, 2025. https:\/\/www.who.int\/publications\/i\/item\/9789241547543"},{"key":"zoi250826r9","unstructured":"Bromley? L, Kahan? M, Regenstreif? L, Srivastava? A, Wyman? J. Methadone treatment for people who use fentanyl: recommendations. META:PHI. Published online June 30, 2021. Accessed August 23, 2024. https:\/\/www.metaphi.ca\/wp-content\/uploads\/Guide_MethadoneForFentanyl.pdf"},{"key":"zoi250826r26","unstructured":"Colorado Department of Public Health and Environment. Drug overdose in Colorado. Accessed November 25, 2024. https:\/\/cdphe.colorado.gov\/colorado-drug-overdose-statistics"},{"key":"zoi250826r27","unstructured":"Jurecka? C, Barocas? JA, Binswanger? I, . Measuring the health impacts of felonizing fentanyl possession: state report. Colorado General Assembly. 2025. Accessed January 22, 2025. https:\/\/drive.google.com\/file\/d\/1aS3QZWGh6cXnlZVQulOvbtr7XMzZ6bjx\/view"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2838107\/christine_2025_oi_250826_1755710569.61933.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T15:31:16Z","timestamp":1756395076000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2838107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.29393","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]}}}